IL-17 enhances the susceptibility of U-2OS osteosarcoma cells to NK cell lysis

被引:34
作者
Honorati, MC
Neri, S
Cattini, L
Facchini, A
机构
[1] Ist Ortoped Rizzoli, Lab Immunol & Genet, I-40136 Bologna, Italy
[2] Univ Bologna, Dipartimento Med Interna & Gastroenterol, I-40138 Bologna, Italy
关键词
IL-17; NK activity; osteosarcoma; adhesion molecules;
D O I
10.1046/j.1365-2249.2003.02234.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We investigated the effect of the proinflammatory cytokine interleukin 17 (IL-17) on the lysis of osteosarcoma cells by human NK cells. NK cells and U-2 OS, MG-63, HOS osteosarcoma cell lines express the IL-17 receptor, the highest amount being found on U-2 OS. Pre-incubation of NK cells with IL-17 did not affect the cytotoxicity against osteosarcomas, that was increased when U-2 OS were preincubated with IL-17. In IL-17 treated U-2 OS osteosarcoma cells FACS analysis demonstrated an increased expression of fibronectin among the panel of adhesion molecules assayed, and the treatment with anti-fibronectin antibodies decreased the NK cytotoxicity. The comparison between interferon gamma (IFN-gamma) treated and IFN-gamma/IL-17-treated U-2 OS showed a decreased susceptibility to NK lysis associated with a reduced expression of CD49f on U-2 OS treated with IFN-gamma/IL-17. IL-17 appears to be a modulator of NK adhesion molecules on U-2 OS cells but antagonizes with IFN-gamma on NK lysis.
引用
收藏
页码:344 / 349
页数:6
相关论文
共 30 条
[1]  
Albanesi C, 1999, J IMMUNOL, V162, P494
[2]  
Ali NN, 1996, J BONE MINER RES, V11, P512
[3]  
AYAD S, 1994, EXTRACELLULAR MATRIX
[4]   Cancer immunotherapy with interleukin-2-activated natural killer cells [J].
Basse, PH ;
Whiteside, TL ;
Herberman, RB .
MOLECULAR BIOTECHNOLOGY, 2002, 21 (02) :161-170
[5]   Cytokines as a link between innate and adaptive antitumor immunity [J].
Belardelli, F ;
Ferrantini, M .
TRENDS IN IMMUNOLOGY, 2002, 23 (04) :201-208
[6]   Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism [J].
Benchetrit, F ;
Ciree, A ;
Vives, V ;
Warnier, G ;
Gey, A ;
Sautès-Fridman, C ;
Fossiez, F ;
Haicheur, N ;
Fridman, WH ;
Tartour, E .
BLOOD, 2002, 99 (06) :2114-2121
[7]   On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy [J].
Bruland, OS ;
Pihl, A .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (11) :1725-1731
[8]   ARE MG-63 AND HOS TE85 HUMAN OSTEOSARCOMA CELL-LINES REPRESENTATIVE MODELS OF THE OSTEOBLASTIC PHENOTYPE [J].
CLOVER, J ;
GOWEN, M .
BONE, 1994, 15 (06) :585-591
[9]  
DEMAEYER E, 1991, CYTOKINE HDB, P215
[10]  
Hirahara N, 2000, ANTICANCER RES, V20, P3137